Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Medications. The original article is from Therapy.

This study examines a combination of ustekinumab plus low‑dose upadacitinib for patients with refractory Crohn’s disease — a group with limited options after failing anti‑TNF and single‑agent therapy. Results could...

This trial is testing an investigational anti-TL1A antibody (tulisokibart/MK-7240) as a potential new treatment for moderate to severe Crohn's disease. Results could affect future treatment options if the drug proves...

A successful Phase 3 trial could provide a new treatment option specifically studied in children with moderate‑to‑severe Crohn's disease, addressing a pediatric population often underrepresented in trials.

The trial is testing risankizumab alone and in combination with investigational ABBV antibodies for moderate-to-severe Crohn’s disease and ulcerative colitis — findings could inform future treatment choices and...

This large register study suggests childhood appendectomy may change later risk of several common conditions while being associated with lower IBD risk — information that could matter to patients, parents, and clinicians...

Small-bowel Crohn's disease often causes strictures and fistulas and typically needs more imaging and procedural care than colonic disease, so patients and clinicians should be aware of its distinct risks and treatment...

The study suggests measurable retinal and choroidal microvascular differences in people with IBD versus controls, which could point to systemic vascular effects of inflammation and offer noninvasive biomarker...

An obituary listing Crohn’s disease and ulcerative colitis as the cause of death is a personal account that can resonate with others affected by IBD and highlights real-world impact on individuals and families.

The study suggests that people with ulcerative colitis who consume diets higher in antioxidant capacity had lower measured disease activity, which could point to diet as a modifiable factor worth exploring alongside...

This study presents an engineered probiotic delivery platform that could improve survival and targeted action of live microbial therapies for IBD, potentially reducing local inflammation while affecting the gut...

This study shows that patients' comfort partly explains how clinical disease activity affects quality of life in ulcerative colitis, suggesting comfort-focused nursing care could help patients feel better even when...

Cure8 found this source from academic.oup.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Ileocecal Resection, and Procedures and surgery. Open the original article for the full...

This review explains how genetic, microbial, immune, and stromal factors interact to cause Crohn’s disease, which helps explain why treatments often need to target specific immune pathways or biologic mechanisms....

Intestinal fibrosis causes strictures that can lead to obstruction and often require surgery; current drugs mainly reduce inflammation and do not reliably prevent or reverse fibrosis. Advances in understanding fibrosis...

Dietary strategies such as the Crohn’s Disease Exclusion Diet (CDED) may help induce remission for some people with Crohn’s disease and could be an option alongside medical therapy or enteral nutrition. Patients...

Colorectal lymphoma in children can mimic IBD flares or cause surgical emergencies; recognizing this can prevent inappropriate escalation of immunosuppression and speed correct diagnosis and treatment.

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Upadacitinib, and JAK inhibitor. The original article is from JAAD case reports.

The study identifies a sizable group of patients in Latin America with difficult-to-treat IBD—especially Crohn’s disease—highlighting higher disease severity, younger onset, and longer diagnostic delays that can affect...

Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.

This study suggests a traditional processing method may change a common herbal used for UC so it works better in mouse and cell models, and it proposes a specific molecular pathway (LCN2‑mediated pyroptosis) that could...

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Adalimumab, and Anti-TNF. The original article is from Journal of Crohn's & colitis.

Researchers are exploring new ways to deliver regenerative factors and reshape the gut microbiome in IBD.

This preclinical study suggests a ginseng-derived polysaccharide reduced inflammation and tissue injury in cell and mouse models of colitis, which could eventually inform dietary supplements or therapeutic research...

Work participation and job retention are common concerns for people living with IBD. This study will measure how IBD affects work ability, fatigue, mental health, and return-to-work barriers, and aims to create...

The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...

A long-term study that profiles immune cells, genes, diet, and the microbiome could help identify biomarkers that predict flares or response to therapy, which matters to people living with Crohn’s or ulcerative colitis.

A new Phase 2 trial is testing MK-8690 as a potential subcutaneous treatment for moderate–severe ulcerative colitis, with clinical remission at 12 weeks as the primary goal. Positive results could point to an additional...

Mentions of Crohn’s disease in obituaries can be relevant to the IBD community as they reflect lived experience and may help raise awareness about disease burden and comorbidities.

Malnutrition is common in Crohn’s disease and more likely during active disease; recognizing it matters because nutritional status affects symptoms, recovery, and treatment tolerance.

Researchers identify a gut microbe (Sutterella species) that may worsen intestinal inflammation by blocking AhR-driven IL-22 and IL-17 responses—pathways that help protect the gut lining.

IBD is increasingly linked with anxiety, depression, and cognitive symptoms; this study suggests gut microbes may change tryptophan metabolism in colitis and contribute to those brain-related symptoms, which could point...

AI tools like Google NotebookLM could make systematic reviews and consensus statement processes faster and less labor-intensive for IBD-related evidence, while maintaining very low rates of major factual errors.

If validated, a blood test for cytotoxic CD4+ T cells at diagnosis could help predict who is less likely to respond to anti‑TNF drugs, potentially allowing earlier selection of alternative therapies for some children...

This review describes a novel, targeted drug-delivery approach being explored for autoimmune diseases including IBD; such technology could in future enable more specific immunomodulation with fewer systemic side effects...

The study shows rapidly rising IBD healthcare costs driven mainly by growing prevalence and biologic therapy spending, which can affect access, insurance coverage, and healthcare planning for people with Crohn’s and...

This study describes a new oral immunoproteasome inhibitor (ent-F10) with preclinical activity in animal models of ulcerative colitis and rheumatoid arthritis, highlighting a potential new drug-development direction that...

This paper links specific features of the gut bacterial flagellome to TLR5-driven immune activation and reports a disease-associated shift in flagellin profiles in Crohn’s disease and ulcerative colitis, suggesting...

This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...

This NIH natural-history study is collecting clinical, immune, and genetic samples from people with Crohn’s disease and ulcerative colitis to better understand immune pathways and molecular causes of IBD. Those findings...

Mucosal healing is an important treatment goal linked to better long-term outcomes, and current anti-TNF therapies achieve mucosal healing in a minority of patients. If adding CDED improves healing, it could offer a...

Patients and families with pediatric UC may be interested because the study tests FMT plus partial enteral nutrition as a potential new treatment approach for children who haven’t responded to standard therapy and as a...

Adding structured partial enteral nutrition to advanced drug therapy could offer a non-pharmacologic way to improve short-term, steroid-free remission rates in active Crohn's disease if the trial shows benefit.

Genetic primary bile acid malabsorption can produce IBD-like symptoms and may be missed in children labeled with Crohn's disease; recognizing PBAM could change testing and management for some patients.

The paper proposes a specific molecular link between elevated glycocholic acid (a bile acid altered in IBD) and impaired intestinal stem cell renewal via the TRIB3–ID1 pathway, which could help explain poor mucosal...

Understanding and quantifying placebo-driven endoscopic changes can improve design and interpretation of Crohn’s disease trials, which may ultimately speed development of effective therapies and clarify who benefits from...

Capsule endoscopy can be helpful for small-bowel assessment in Crohn’s disease but carries a risk of retention when strictures are present. Retained capsules may be asymptomatic yet still require surgery, so better...

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Aminosalicylates. The original article is from Digestive Diseases and Sciences.